Navigation Links
Data from Patient Subsets of e-HEALING, a Worldwide Registry, Support Use of OrbusNeich's Genous(TM) Bio-Engineered R Stent(TM) as Alternative to Drug- Eluting Stents
Date:9/3/2007

Report of Positive Results with Innovative Pro-Healing Stent is Featured at

ESC Congress 2007

VIENNA, Austria, Sept. 3 /PRNewswire/ -- OrbusNeich today announced that post-marketing data from patient subsets of a global registry support the use of the company's Genous(TM) Bio-engineered R stent(TM) as an alternative to drug-eluting stents.

Presented today by Robbert de Winter, M.D., Ph.D., at the European Society of Cardiology (ESC) Congress 2007 in Vienna, Austria, the data from OrbusNeich's e-HEALING registry show:

* For 296 diabetic patients at six months, the target lesion

revascularization (TLR) rate was 2%, which is much lower than was

anticipated

* A TLR rate of 1.9% for 213 chronic total occlusion (CTO) patients at ]

six months

* For 923 patients with statin use, the major adverse cardiac events

(MACE) rate at six months was 5.7%, while 116 patients without statin

use experienced a MACE rate of 6.9% over the same period

"This real-world data strengthen our belief that Genous is a very promising alternative to drug-eluting stents," said de Winter, a co-principal investigator of the study and director of the catheterization laboratory at the Academic Medical Center in Amsterdam. "Genous appears to have the same efficacy as drug-eluting stents but a better safety profile with only minimal dual-antiplatelet therapy requirements. This is an important finding in that physicians are becoming reluctant to burden their patients with the cost and compliance issues associated with drug-eluting stents and their extensive dual-antiplatelet therapy requirements."

OrbusNeich's e-HEALING is a multi-center, worldwide (outside the United States) prospective registry of patients treated with the Genous Bio- engineered R stent in accordance with the instructions for use. The protocol recommends that patients receive two weeks of statin treatment prior to the procedure and one month of clopidogrel treatment after the procedure. Clinical follow-up takes place at 30 days, six months and 12 months. The primary outcome of the registry is target vessel failure at 12 months.

Unlike drug-eluting stents, Genous, which is coated with an antibody, captures a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process. EPCs circulate in the bloodstream and are involved in the repair of blood vessels. When attracted to the surface of Genous, EPCs rapidly form an endothelial layer over the stent that provides protection against thrombus and minimizes restenosis.

OrbusNeich designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. The company's product portfolio includes the Genous(TM) Bio-engineered R stent(TM), an antibody- coated device that is the first-ever stent to capture a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process following placement. Other products are stents, balloons and guiding catheters marketed under the names of Blazer(TM), R stent(TM), Sapphire(TM), Avita(TM), Avita HP(TM), SafeCut(TM), Lumina(TM) and Saffron.

A global company, OrbusNeich is headquartered in Hong Kong and has operations in Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Shenzhen, China. OrbusNeich, which has provided cardiology devices to physicians through its predecessor companies since 1979, today supplies products in more than 60 countries. For more information, visit http://www.OrbusNeich.com.


'/>"/>
SOURCE OrbusNeich
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. One in Three Heart Attack Patients Have No Chest Pains
2. Amphetamines Help Recovery of Stroke Patients
3. Painkillers Do Not Shorten Dying Patients Lives
4. Patients With Filariasis More Prone To HIV Infection
5. Glivec - New Hope For CMC Patients
6. Patient’s perception of health status helps in better recover
7. HIV infected patients can travel safely abroad
8. New vaccine helps allergy and asthma patients
9. Doctors operate upon patients in candlelight- latest from the quake scene
10. New vaccine helps allergy and asthma patients
11. Are cancer patients being taken for a ride?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/13/2017)... ... January 13, 2017 , ... The 18th European Congress: Perspectives in ... March 3-4, 2017. This Congress is expertly designed to meet the educational needs ... with lung cancer. , Chaired by Dr. Giorgio V. Scagliotti, Professor of Oncology at ...
(Date:1/13/2017)... ... ... inventor from Pahrump, Nev., used an unsavory medical experience to think of a way to ... urine bag for a half year due to lazy bladder," he said. "Keeping these things ... better way to do this." , He then designed and created a prototype of the ...
(Date:1/13/2017)... , ... January 13, 2017 , ... Friday, January 13 ... of the game room, increasing the size of the location to 90,000 square feet. ... 8-hole mini golf course that takes customers on an educational tour of the historic ...
(Date:1/13/2017)... ... January 13, 2017 , ... As the nation watches this month’s transition ... colleges and schools of education across the country is urging a fundamental reconsideration of ... Principles released today, 175 deans sounded the alarm: “Our children suffer when we deny ...
(Date:1/13/2017)... ... January 13, 2017 , ... One way to obtain a green card is ... can show their work is in the national interest. There are two significant advantages ... be sponsored by an employer; and 2) the submission is made directly to the ...
Breaking Medicine News(10 mins):
(Date:1/12/2017)... -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company developing ... this week,s Orlando Dermatology Aesthetic & Clinical (ODAC) Conference, which ... inflammation. The data will be shared in a ... at ODAC, which is being held Jan. 13-16 in ... ...
(Date:1/12/2017)...   TyrNovo , s NT219 drug candidate ... cancer drug resistance and would be ... NT219 is a novel proprietary ... ( IRS1/2 and STAT3) highly involved in ... .   NT219 has demonstrated ...
(Date:1/12/2017)... -- "Global Lung Cancer Vaccine Market & Pipeline ... trends in the global lung cancer vaccine market. ... available in the market. This report analyzes the ... in clinical pipeline and gives comprehensive clinical insight ... the lung cancer vaccines. Currently there are 9 ...
Breaking Medicine Technology: